ALNYLAM PHARMACEUTICALS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-07-30
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $8.82M.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $3.84M, a 98.14% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-06-30 was -$1.29M, a 118.36% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-03-31 was $9.83M, a 1169.51% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $21.20M, a 127.68% increase from fiscal 2024.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $9.31M, a 262.22% increase from fiscal 2023.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $2.57M, a 153.70% increase from fiscal 2022.
- ALNYLAM PHARMACEUTICALS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $1.01M, a 87.23% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-07-30 | |||
| 2025-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $12.66M derived: sum of 2 quarters · filed 2026-02-12 | $11.37M derived: sum of 3 quarters · filed 2026-07-30 | $21.20M 10-K · filed 2026-02-12 |
| 2025-09-30 | $3.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $2.55M derived: sum of 2 quarters · filed 2026-07-30 | $12.38M 10-Q · filed 2025-10-30 | $11.96M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | -$1.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $8.54M 10-Q · filed 2026-07-30 | $8.11M derived: sum of 3 quarters · filed 2026-07-30 | $10.05M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $9.83M 10-Q · filed 2025-05-01 | $9.40M derived: sum of 2 quarters · filed 2026-02-12 | $11.34M derived: sum of 3 quarters · filed 2026-02-12 | $18.36M derived: sum of 4 quarters · filed 2026-02-12 |
| 2024-12-31 | -$423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $1.52M derived: sum of 2 quarters · filed 2026-02-12 | $8.54M derived: sum of 3 quarters · filed 2026-02-12 | $9.31M 10-K · filed 2026-02-12 |
| 2024-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $8.96M derived: sum of 2 quarters · filed 2025-10-30 | $9.73M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $7.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $7.79M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | $774.00K 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | $2.57M 10-K · filed 2026-02-12 | |||
| 2022-12-31 | $1.01M 10-K · filed 2025-02-13 | |||
| 2021-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $2.62M derived: sum of 2 quarters · filed 2023-02-23 | $7.93M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $2.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $7.88M 10-Q · filed 2021-10-28 | ||
| 2021-06-30 | $5.31M 10-Q · filed 2021-08-03 | |||
| 2020-12-31 | $72.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $19.36M derived: sum of 2 quarters · filed 2023-02-23 | $31.50M derived: sum of 3 quarters · filed 2023-02-23 | $34.44M 10-K · filed 2023-02-23 |
| 2020-09-30 | $19.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28 | $31.42M derived: sum of 2 quarters · filed 2021-10-28 | $34.36M 10-Q · filed 2021-10-28 | $36.35M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-06-30 | $12.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $15.08M 10-Q · filed 2021-08-03 | $17.06M derived: sum of 3 quarters · filed 2022-02-10 | $17.88M derived: sum of 4 quarters · filed 2022-02-10 |
| 2020-03-31 | $2.94M 10-Q · filed 2020-05-06 | $4.92M derived: sum of 2 quarters · filed 2022-02-10 | $5.74M derived: sum of 3 quarters · filed 2022-02-10 | $7.47M derived: sum of 4 quarters · filed 2022-02-10 |
| 2019-12-31 | $1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-10 | $2.80M derived: sum of 2 quarters · filed 2022-02-10 | $4.53M derived: sum of 3 quarters · filed 2022-02-10 | $4.53M 10-K · filed 2022-02-10 |
| 2019-09-30 | $818.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $2.55M derived: sum of 2 quarters · filed 2020-11-05 | $2.55M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $1.73M 10-Q · filed 2020-08-06 | ||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |